Posted by Michael Wonder on 06 Jul 2022
NICE recommends Janssen’s treatment for active psoriatic arthritis
6 July 2022 - Clinical trial evidence suggests that Tremfya is effective when compared with a placebo
Tremfya – also known as guselkumab – has been recommended by NICE for patients with active psoriatic arthritis whose disease does not respond to conventional disease-modifying anti-rheumatic drugs.
